GILD

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines in areas of unmet medical need, with a focus on antiviral therapies, oncology, and inflammatory diseases. The company is a leader in HIV treatment with its portfolio including Biktarvy, Descovy, and Truvada, and has expanded into hepatitis C treatments, COVID-19 therapeutics (remdesivir/Veklury), and cancer therapies through its acquisition of Kite Pharma. Gilead operates globally with research facilities and commercial operations across North America, Europe, and Asia. The company invests heavily in research and development while maintaining one of the pharmaceutical industry's most profitable product portfolios.